- Title
- A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
- Creators
- Melissa Alsina - Moffitt Cancer CenterOla Landgren - Memorial Sloan Kettering Cancer CenterNoopur Raje - Massachusetts General HospitalRuben Niesvizky - Presbyterian HospitalWilliam I. Bensinger - Swedish Medical CenterJesus G. Berdeja - Sarah CannonTibor Kovacsovics - Huntsman Cancer InstituteDavid H. Vesole - Hackensack University Medical CenterBelle Fang - AmgenAmy S. Kimball - AmgenDavid S. Siegel - Hackensack University Medical CenterCarl Ola Landgren - Miller School of Medicine
- Publication Details
- American journal of hematology, Vol.96(2), pp.226-233
- Academic Unit
- Miller School of Medicine; UMMG Department of Medicine
- Language
- English
- Resource Type
- Journal article
- PMID
- 33125764
- Record Identifier
- 991031714348202976
Journal article
A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
American journal of hematology, Vol.96(2), pp.226-233
2021-02
PMID: 33125764
Metrics
2 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.130 Lymphomas
- 1.130.617 Multiple Myeloma
- Web Of Science research areas
- Hematology
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites